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Abstract
Introduction The coronavirus disease (COVID-19) pandemic has changed routine clinical practice worldwide with major
impacts on the provision of care and treatment for stroke patients.
Methods This retrospective observational study included all patients admitted to the Royal Stoke University Hospital in Stoke-
on-Trent, UK, with a stroke or transient ischaemic attack between March 15th and April 14th, 2020 (COVID). Patient demo-
graphics, characteristics of the stroke, treatment details and logistics were compared with patients admitted in the corresponding
weeks in the year before (2019).
Results There was a 39.5% (n = 101 vs n = 167) reduction in admissions in the COVID cohort compared with 2019 with more
severe strokes (median National Institutes of Health Stroke Scale (NIHSS) 7 vs 4, p = 0.02), and fewer strokes with no visible
acute pathology (21.8 vs 37.1%, p = 0.01) on computed tomography. There was no statistically significant difference in the rates
of thrombolysis (10.9 vs 13.2%, p = 0.72) and/or thrombectomy (5.9 vs 4.8%, p = 0.90) and no statistically significant difference
in time from stroke onset to arrival at hospital (734 vs 576min, p = 0.34), door-to-needle time for thrombolysis (54 vs 64min, p =
0.43) and door-to-thrombectomy time (181 vs 445 min, p = 0.72). Thirty-day mortality was not significantly higher in the
COVID year (10.9 vs 8.9%, p = 0.77). None of the 7 stroke patients infected with COVID-19 died.
Conclusions During the COVID-19 pandemic, the number of stroke admissions fell, and stroke severity increased. There was no
statistically significant change in the delivery of thrombolysis and mechanical thrombectomy and no increase in mortality.
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Introduction
Coronavirus disease 2019 (COVID-19) is an infectious dis-
ease caused by the SARS-CoV-2 virus. As of September 21st,
2020, there are 30,675,675 confirmed COVID-19 cases and
954,417 confirmed deaths in over 216 countries/territories
worldwide [1]. The United Kingdom (UK), with 390,362 con-
firmed cases and 41,759 confirmed deaths, continues to have
community transmission at present [1]. COVID-19 is associ-
ated with a hypercoagulable state that may lead to an increase
in acute cerebrovascular events with an increase in ischaemic
strokes and large vessel occlusion strokes [2–4]. Preliminary
global reports show a reduction in the number of stroke ad-
missions with a delay in the presentation of acute ischaemic
strokes and time to thrombolysis and thrombectomy [5–7].
The response to the coronavirus disease (COVID-19) pan-
demic saw organisations across the UK using varied strategies
to approach changes in routine clinical practice. The Hyper
Acute Stroke Unit in the Royal Stoke University Hospital also
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adopted a new model. Outpatient clinics with direct patient
contact were closed and replaced by virtual clinics. All holi-
days, study leave and non-clinical activity were cancelled,
thereby increasing the shop floor presence of nursing and
medical workforce. The junior doctor schedule was changed
from the standard 9 am to 5 pm working hours to a more
widely distributed 24 h round the clock availability on the
ward with reduced additional speciality responsibilities.
The UK went into lockdown onMarch 23rd, 2020, and the
COVID-19 pandemic began in Stoke-on-Trent in the West
Midlands around March 15th, 2020. Our study aimed to es-
tablish whether and how the delivery of stroke care during this
period was affected by the COVID-19 pandemic. We did this
by comparing 4 weeks when we had the highest number of
COVID-19 cases in 2020 with the same period in the year
before. The aim of this was to see whether there were any
changes to the number of stroke unit admissions in the
COVID year.
Methods
Study design and setting
This retrospective observational study was based at the Hyper
Acute Stroke Unit (HASU) in the Royal Stoke University
Hospital, Stoke-on-Trent, UK. The 32-bedded comprehensive
tertiary stroke centre at the Royal Stoke University Hospital in
Stoke-on-Trent caters to a local population of half a million
individuals. We receive secondary referrals from three district
general hospitals and tertiary referrals for mechanical
thrombectomy from four acute stroke units. Situated in a re-
gion with a high prevalence of vascular co-morbidity due to
high unemployment, the unit has a secondary catchment area
of 1.5 million and a tertiary catchment area of 3 million with
around 1250 stroke admissions every year.
Two cohorts were identified for this study from local
Sentinel Stroke National Audit Programme data. The
Sentinel Stroke National Audit Programme database records
all patients admitted to the hospital with a stroke diagnosis.
This includes patients who are not admitted to the Hyper
Acute Stroke Unit. Cohort 1 (COVID) included all patients
admitted to the hospital during the first 4 weeks of the
COVID-19 pandemic with a diagnosis of stroke/stroke mim-
ic/transient ischaemic attack (TIA), i.e. between March 15th
and April 14th, 2020. All patients admitted with a stroke re-
ceived care on the Hyper Acute Stroke Unit during this period.
Cohort 2 (pre-COVID) included all patients admitted to the
hospital during the corresponding weeks in the previous year,
i.e. between March 15th and April 14th, 2019. Patients who
were not admitted with a diagnosis of stroke/TIA/stroke mim-
ic were excluded.
Data collection
Data on patient demographics, characteristics of stroke, the
time between onset and hospital presentation, treatment de-
tails and outcomes were included in this study analysis. Data
were extracted from the local Sentinel Stroke National Audit
Programme database and from the hospital’s electronic health
records system. This includes discharge letters, blood results
and imaging results. The ward admissions’ book and patient
notes were also accessed to gather information.
Plan of analysis/statistical tools
Data was entered and summarised in Microsoft Excel.
Categorical variables were compared by means of Z test (bi-
nary variables), Chi-squared test (categorical variables with 3
or more categories) and Fisher’s exact test (low expected per-
cell observations). The Kolmogorov-Smirnov test was used to
assess normality of continuous variables (age, National
Institutes for Health Stroke Scale (NIHSS) score and timings)
which were subsequently compared using Student t test or
Mann-Whitney U test for normally distributed and non-
normal data, respectively. Statistical analysis was done in R
statistical software tool (R Core Team, 2018). Significance
was accepted at p < 0.05.
Results
There were 101 and 167 admissions with stroke/TIA/stroke
mimic in the COVID cohort and the pre-COVID cohort, re-
spectively, representing 39.5% fewer admissions during the
COVID pandemic peak (Table 1). In the COVID cohort, 7
(6.9%) were positive for SARS-CoV-2 virus on polymerase
chain reaction testing. No tests were done in 2019 (Table 1).
Themean age of patientswas 70.4 SD 14.9/73.2 SD 13.8 years
in the COVID and pre-COVID cohorts, with just under 50%
females (47.5 vs 49.1%) and a high proportion of White eth-
nicity (90.1 vs 88.6%). There was no statistically significant
difference in any of these characteristics between the two co-
horts (Table 2).
Table 1 Comparison of stroke admissions during COVID year and pre-
COVID year
COVID Pre-COVID
Number of stroke admissions 101 167
COVID-19 positive (n (%)) 7 (6.9%) N/A
COVID-19 mortality (n (%)) 0 (0.0%) N/A
n, number of patients
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The final diagnosis was s t roke ( ischaemic or
haemorrhagic) in 92 (91.1%)/145 (86.8%), transient ischemic
attack in 0 (0%)/2 (1.2%) and stroke mimic in 9 (8.9%)/20
(12.0%) in the COVID and pre-COVID cohorts, respectively.
Among the strokes, 70 (69.4%)/121 (72.2%) were ischaemic,
and 22 (21.8%)/24 (14.4%) were haemorrhagic in the two
respective cohorts. None of the differences was statistically
significant (Table 3).
Stroke severity was significantly higher in the COVID co-
hort than in the pre-COVID cohort (median (IQR) NIHSS 7
(3–16) vs 4 (2–12), p = 0.02). Significantly fewer patients had
no acute findings (ischaemia or haemorrhage) on imaging in
the COVID cohort than pre-COVID (22 (21.8%) vs 62
(37.1%), p = 0.01) (Table 3).
There were no statistically significant differences in the
rates of thrombolysis (11 (10.9%) vs 22 (13.2%)) and me-
chanical thrombectomy (6 (5.9%) vs 8 (4.8%)) between the
COVID and pre-COVID cohorts. Moreover, no statistically
significant difference was found between cohorts in the time
from onset to hospital arrival (median 734 vs 576 min), door
to thrombolysis time (mean 54 vs 64 min) and door to groin
time for mechanical thrombectomy (mean 181 vs 445 min)
(Table 4).
Thirty-day mortality was similar between the COVID
and pre-COVID cohorts (11 (10.9%) vs 15 (8.9%), p =
0.77). There were no deaths among COVID-positive pa-
tients, and there was no statistically significant differ-
ence in stroke recurrence (4 (3.9%) vs 13 (7.8%), p =
Table 3 Characteristics of stroke
in the COVID and pre-COVID
cohorts
n (%) except where indicated COVID (n = 101) Pre-COVID (n = 167) p value
Final diagnosis
Stroke (ischemic or haemorrhagic) 92 (91.1%) 145 (86.8%) 0.39a
Transient ischaemic attack 0 (0%) 2 (1.2%) 0.53d
Stroke mimic 9 (8.9%) 20 (12.0%) 0.56a
Radiological findings
Visible acute infarct on imaging 57 (56.4%) 81 (48.5%) 0.26a
Primary intracerebral haemorrhage 22 (21.8%) 24 (14.4%) 0.16a
No acute ischemia or haemorrhage 22 (21.8%) 62 (37.1%) 0.01a
Stroke severity
NIHSS (median (IQR)) 7 (3–16) 4 (2–12) 0.02b
Mild stroke (NIHSS 0–3) 31 (30.7%) 71 (42.5%) 0.14c
Moderate stroke (NIHSS 4–8) 27 (26.7%) 43 (25.8%)
Severe stroke (NIHSS > 8) 43 (42.6%) 53 (31.7%)
Bamford classification
Total anterior circulation infarct 21 (20.8%) 32 (19.1%) 0.87a
Partial anterior circulation infract 15 (14.9%) 35 (20.9%) 0.28a
Lacunar infarct 21 (20.8%) 44 (26.3%) 0.38a
Posterior circulation infarct 13 (12.9%) 10 (5.9%) 0.08a
Haemorrhagic stroke 22 (21.8%) 24 (14.4%) 0.16a
IQR, interquartile range; n, number of patients; NIHSS, National Institutes of Health Stroke Scale
a Z test
bMann-Whitney U test
c Chi-squared test
d Fisher’s exact test
Table 2 Demographic details of
stroke admissions in the COVID
and pre-COVID cohorts
Demographics COVID (n = 101) Pre-COVID (n = 167) p value
Age mean (SD) 70.4 (14.9) 73.2 (13.8) 0.13a
Female sex (n (%)) 48 (47.5%) 82 (49.1%) 0.90b
Ethnicity White (n (%)) 91 (90.1%) 148 (88.6%) 0.86b
Ethnicity Non-White/not specified (n (%)) 10 (9.9%) 19 (11.4%)
n, number of patients; SD, standard deviation
a t test
b Z test
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0.32) and discharge destination between the cohorts
(Table 5).
Discussion
The key findings of this project are a reduction in the total
number of stroke admissions and an increase in stroke severity
during the COVID-19 pandemic. There was no statistically
significant change in the rates and timings of delivery of
thrombolysis and mechanical thrombectomy, and no worsen-
ing of stroke outcomes during the pandemic.
During the same time periods, the West Midlands
Ambulance Service University NHS Foundation Trust
Ambulance Service, which covers the Royal Stoke
University Hospital and the wider West Midlands region, re-
ported no reduction in callouts for stroke [8]. While this data
suggests that the same number of people are calling 999 with
acute stroke symptoms, fewer are admitted with a diagnosis of
stroke. It is possible that patients with milder symptoms were
treated on-site rather than taken to the hospital. We have no
details to confirm this. However, our observation of greater
stroke severity in admitted patients lends some support to this
possibility. Patients who did not present to the hospital were
not captured as there is no community stroke registry.
Fewer callouts resulting in a transfer to a hospital may have
been due to national guidance to avoid hospital admission,
wherever possible, or because of patients refusing transfer to
hospital because of fear of COVID-19. Rudilosso et al. report
an increase in daily emergency phone calls with a fall in the
number of stroke admissions during their COVID peak in
Barcelona [9]. In contrast, teams from Seville and Ohio report
significant decreases in their daily stroke alerts and telephone
stroke consultations [5, 10]. The reason for these differences
between centres is not apparent. Zhao et al. report a significant
drop in the hospital admissions for stroke during COVID-19
pandemic in China [11]. Amulticentre study byHoyer et al. in
Germany reports a significant reduction in acute stroke and
TIA admissions following the implementation of national
lockdown and decreased public mobility [12].
In our cohort, stroke patients presented with a higher me-
dian NIHSS with no statistically significant difference in the
stroke demographics, i.e. age, sex and ethnicity. This is dif-
ferent from Rudilosso et al., who report younger strokes, but
no difference in severity at presentation [9].
We did not find a significant increase in the time between
symptom onset and arrival at the hospital. This mirrors find-
ings fromOhio and Barcelona [5, 9]. However, Schirmer et al.
and Montaner et al. describe a significant increase in stroke
onset time to arrival at the hospital during the COVID-19
Table 4 Impact of COVID-19 on
frequency and timing of
thrombolysis and mechanical
thrombectomy
COVID (n = 101) Pre-COVID (n = 167) p value
Thrombolysis (n (%)) 11 (10.9%) 22 (13.2%) 0.72a
Mechanical thrombectomy (n (%)) 6 (5.9%) 8 (4.8%) 0.90a
Time from onset to arrival (median (IQR)) min 734 (246–1091) 576 (128–1197) 0.34b
Time from arrival to thrombolysis (mean SD) min 54 (30) 64 (47) 0.43c
Time from arrival to thrombectomy (mean SD) min 181 (62) 445 (566) 0.72c
IQR = interquartile range; n = number of patients; SD = standard deviation
a Z test
bMann-Whitney U test
c t test
Table 5 Impact of COVID-19 on
stroke outcome Outcome n (%) COVID (n = 101) Pre-COVID n = 167 p value
30-day mortality 11 (10.9%) 15 (8.9%) 0.77a
Stroke recurrence 4 (3.9%) 13 (7.8%) 0.32a
Discharged to home/care home 59 (58.4%) 106 (63.5%) 0.28b
Discharged to another acute setting 17 (16.8%) 36 (21.5%)
Discharged to an inpatient rehabilitation centre 15 (14.9%) 14 (8.4%)
Death during hospital stay 10 (9.9%) 11 (6.6%)
n, number of patients
a Z test
b 2x4 Chi-squared test
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period for a collaboration of 12 hospitals in 6 states in the
USA and Seville in Spain, respectively [6, 10]. This is similar
to Frisullo et al., who reported a significant increase in the
onset-to-door time in the early phase of the pandemic in
Rome [13]. Such differences may reflect different policies in
prioritisation of stroke transfer and/or differing strain on
existing services due to high numbers of COVID-19 patients.
In our study, neither the proportion of patients treated with
thrombolysis and/or thrombectomy nor the timeliness of in-
terventions differed significantly to the year before the
COVID pandemic. However, numbers were small, making
point estimates imprecise. Lower rates of intravenous throm-
bolysis and thrombectomy were reported from Spain and
China where their health services were overrun [9–11]. A
study conducted in France showed significant delays between
imaging and groin puncture timings during the COVID-19
period. However, this difference was not significant when
patients underwent thrombectomy at the first hospital that they
presented to [7]. A study of 17 thrombectomy centres in
Europe, Canada and the USA showed a significant decrease
in the number of thrombectomies performed and an increase
in stroke onset-to groin puncture after confinement measures
were put in place [14].
In the UK, the medical service was not overwhelmed, but
we did have higher mortality in the COVID year. A pooled
analysis by Aggarwal shows increased odds of severe cere-
brovascular disease in COVID-19-infected patients [15]. This
is unlike our experience. Stroke mortality has not increased
despite greater severity, and there was no statistically signifi-
cant change in outcomes at discharge. We have been able to
maintain quality care with comparable outcomes and without
significant mortality.
It can be hypothesised that a lower number of stroke ad-
missions allowed us to provide a better service to the individ-
ual. In addition, cancellation of all non-clinical tasks, annual
and study leave compensated for staff absences through
COVID-19 infection and quarantine, freed up consultant time
and increased consultant presence on the ward. Junior doctor
workforce was more evenly distributed throughout the
24 hours, and this may have allowed for earlier detection
and treatment of complications. The greater presence of med-
ical staff translated to lower threshold for nurses to contact
doctors of all grades for advice which led to focussed assess-
ments and improved patient care. While service was provided
as usual for patients who presented to the hospital, secondary
prevention may have been missed out for patients who did not
present themselves. For future pandemics, this needs to be
managed proactively by raising public awareness, liaison with
ambulance services, and general practitioners, and the provi-
sion of ‘catch-up’ services to maintain secondary prevention
and prevent avoidable strokes.
Locally, the change in number and severity of stroke pa-
tients prompted a public awareness campaign via local Stoke-
on-Trent news and radio interviews during the month of May
highlighting concerns over the drop in stroke admissions in
our region and advising the public to seek help from the
National Health Service (NHS) if they experience symptoms
of a stroke [16]. There was a special focus on people with
minor stroke symptoms and elderly isolated patients. A week
later, the National Health Service ‘Help Us Help You’ cam-
paign by the British Government also urged the public to
continue to act FAST (face, arms, speech, time) by calling 999
for stroke symptoms [17].
The main limitation of our study is that it is from a single
hospital. Numbers are therefore too small to detect small, but
potentially important differences reliably. It will be important
to see whether our findings are reflected elsewhere in the UK
and whether the trend of admissions is due to fewer patients
presenting, or fewer patients who call 999 being admitted to
hospital.
Conclusion
We provide evidence that stroke admissions have reduced by
two-fifths during the COVID-19 pandemic, but that admitted
stroke patients had greater neurological deficits. Rate of deliv-
ery of hyperacute interventions such as thrombolysis and me-
chanical thrombectomy was unchanged, and there was no
increase in mortality or adverse discharge outcomes. Our find-
ings contribute to the knowledge base of the effect of service
changes on outcomes in times of exceptional stress on the
health system.
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